1h Free Analyst Time
The publisher's latest Pharmaceutical and Healthcare disease pipeline guide Psoriatic Arthritis - Drugs In Development, 2022, provides an overview of the Psoriatic Arthritis (Musculoskeletal Disorders) pipeline landscape.Speak directly to the analyst to clarify any post sales queries you may have.
Psoriatic arthritis is a form of arthritis that affects some people who have psoriasis. Symptoms include swollen fingers and toes, foot pain and lower back pain. Risk factors include age, family history and psoriasis. Treatment includes NSAIDs, immunosuppressants and surgery.
Report Highlights
The publisher's Pharmaceutical and Healthcare latest pipeline guide Psoriatic Arthritis - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Psoriatic Arthritis (Musculoskeletal Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.The Psoriatic Arthritis (Musculoskeletal Disorders) pipeline guide also reviews of key players involved in therapeutic development for Psoriatic Arthritis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 5, 15, 6, 17, 2, 27, 13 and 2 respectively.
Psoriatic Arthritis (Musculoskeletal Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Psoriatic Arthritis (Musculoskeletal Disorders).
- The pipeline guide reviews pipeline therapeutics for Psoriatic Arthritis (Musculoskeletal Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Psoriatic Arthritis (Musculoskeletal Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Psoriatic Arthritis (Musculoskeletal Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Psoriatic Arthritis (Musculoskeletal Disorders)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Psoriatic Arthritis (Musculoskeletal Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Psoriatic Arthritis (Musculoskeletal Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
- Introduction
- Report Coverage
- Psoriatic Arthritis - Overview
- Psoriatic Arthritis - Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Products under Development by Companies
- Psoriatic Arthritis - Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Psoriatic Arthritis - Companies Involved in Therapeutics Development
- Psoriatic Arthritis - Drug Profiles
- Psoriatic Arthritis - Dormant Projects
- Psoriatic Arthritis - Discontinued Products
- Psoriatic Arthritis - Product Development Milestones
- Featured News & Press Releases
- Sep 26, 2022: MoonLake Immunotherapeutics to initiate global phase 2 study of the Nanobody sonelokimab in patients with active psoriatic arthritis
- Sep 12, 2022: Cosentyx 300 mg Pen Approved in Japan: Novartis
- Sep 10, 2022: AbbVie showcases new analyses and real-world data across multiple immune-mediated skin diseases at the European Academy of Dermatology and Venereology (EADV) 2022 Congress
- Sep 10, 2022: New late-breaking results from phase 3 trials of SKYRIZI (risankizumab) evaluating long-term effect on skin and joint symptoms in patients with psoriatic arthritis at Week 100
- Aug 24, 2022: Nimbus Therapeutics presents new data on oral allosteric TYK2 inhibitor at American Chemical Society Meeting
- Aug 15, 2022: Ventyx Biosciences to report topline results from the phase 1 trial of its TYK 2 inhibitor VTX958 and second quarter 2022 financial results on August 15, 2022
- Aug 15, 2022: Ventyx Biosciences announces positive topline phase 1 data for its selective allosteric TYK2 inhibitor VTX95
- Aug 02, 2022: US FDA grants approval for Janssen’s Stelara to treat psoriatic arthritis
- Jul 21, 2022: Sandoz Supplemental Biologics License Application accepted by US FDA for biosimilar Hyrimoz (adalimumab-adaz) high concentration formulation (HCF)
- Jun 04, 2022: New data show patients treated with first-in-Class TREMFYA (guselkumab) achieve durable efficacy across joint and axial Symptoms of active psoriatic arthritis through two years
- Jun 03, 2022: ACELYRIN, Affibody and Inmagene Biopharmaceuticals announce data from global phase 2 trial of Izokibep in patients with psoriatic arthritis presented during 2022 European Alliance of Associations for Rheumatology Congress
- May 23, 2022: UCB announces first detailed data from two phase 3 bimekizumab studies in psoriatic arthritis to be presented at EULAR 2022
- May 18, 2022: New data show TREMFYA (guselkumab) binds to both inflammatory cells and interleukin (IL)-23, supporting a hypothesis for a differentiated mechanism from Risankizumab
- May 16, 2022: Alvotech announces positive results from a pharmacokinetic similarity study for AVT04, a proposed biosimilar to Stelara
- May 12, 2022: Amgen and Lance bBass partner to encourage people to do a 'double take' to recognize the early signs of psoriatic arthritis
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact the Publisher
- Disclaimer
- Number of Products under Development for Psoriatic Arthritis, 2022
- Number of Products under Development by Companies, 2022
- Products under Development by Companies, 2022
- Number of Products by Stage and Target, 2022
- Number of Products by Stage and Mechanism of Action, 2022
- Number of Products by Stage and Route of Administration, 2022
- Number of Products by Stage and Molecule Type, 2022
- Psoriatic Arthritis - Dormant Projects, 2022
- Psoriatic Arthritis - Discontinued Products, 2022
- Number of Products under Development for Psoriatic Arthritis, 2022
- Number of Products under Development by Companies, 2022
- Number of Products by Top 10 Targets, 2022
- Number of Products by Stage and Top 10 Targets, 2022
- Number of Products by Top 10 Mechanism of Actions, 2022
- Number of Products by Stage and Top 10 Mechanism of Actions, 2022
- Number of Products by Routes of Administration, 2022
- Number of Products by Stage and Routes of Administration, 2022
- Number of Products by Molecule Types, 2022
- Number of Products by Stage and Molecule Types, 2022
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- 3SBio Inc
- AbbVie Inc
- Acelyrin Inc
- Aclaris Therapeutics Inc
- Alpine Immune Sciences Inc
- AltruBio Inc
- Alvotech SA
- Amgen Inc
- Avesthagen Ltd
- Avotres Inc
- Azora Therapeutics Australia Pty Ltd
- Bio-Thera Solutions Ltd
- Biocad
- Biocon Ltd
- Biogen Inc
- BiondVax Pharmaceuticals Ltd
- BiosanaPharma BV
- Bioviz Technologies Pvt Ltd
- BioXpress Therapeutics SA
- Bristol-Myers Squibb Co
- Cantargia AB
- Celltrion Inc
- Celon Pharma SA
- DM Bio Ltd
- DNX Biopharmaceuticals Inc
- Dong-A ST Co Ltd
- Eli Lilly and Co
- f5 Therapeutics Inc
- Formycon AG
- Galapagos NV
- Huabo Biopharm (Shanghai) Co Ltd
- Immunwork Inc
- Innovimmune Biotherapeutics Inc
- Jiangsu Hengrui Medicine Co Ltd
- JiangSu Qyuns Therapeutics Co Ltd
- Johnson & Johnson
- Kangpu Biopharmaceuticals Ltd
- Luye Pharma Group Ltd
- Mabpharm Ltd
- Machavert Pharmaceuticals LLC
- Microba Life Sciences Ltd
- MoonLake Immunotherapeutics
- Mycenax Biotech Inc
- NeuClone Pty Ltd
- Nimbus Therapeutics LLC
- Novartis AG
- Pfizer Inc
- Pharmapraxis
- Polpharma Biologics SA
- Protein Foundry LLC
- Rani Therapeutics LLC
- Sagacity pharmaceuticals
- Samsung Bioepis Co Ltd
- Sandoz International GmbH
- Shanghai Henlius Biotech Inc
- Shanghai Junshi Bioscience Co Ltd
- Siam Bioscience Co Ltd
- Sun Pharma Advanced Research Company Ltd
- SynAct Pharma AB
- UCB SA
- Vascular Biogenics Ltd
- Ventyx Biosciences Inc
- XBiotech Inc
- XinThera Inc
